KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesChange in TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

AbCellera Biologics (ABCL) Change in Receivables: 2020-2025

Historic Change in Receivables for AbCellera Biologics (ABCL) over the last 6 years, with Sep 2025 value amounting to $3.4 million.

  • AbCellera Biologics' Change in Receivables fell 82.68% to $3.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $36.8 million, marking a year-over-year decrease of 43.09%. This contributed to the annual value of $75.1 million for FY2024, which is 63.54% up from last year.
  • Latest data reveals that AbCellera Biologics reported Change in Receivables of $3.4 million as of Q3 2025, which was down 69.86% from $11.4 million recorded in Q2 2025.
  • Over the past 5 years, AbCellera Biologics' Change in Receivables peaked at $32.2 million during Q2 2023, and registered a low of -$7.9 million during Q1 2023.
  • Its 3-year average for Change in Receivables is $12.5 million, with a median of $11.4 million in 2025.
  • Data for AbCellera Biologics' Change in Receivables shows a peak YoY increase of 1,900.00% (in 2023) and a maximum YoY decrease of 190.45% (in 2023) over the last 5 years.
  • Quarterly analysis of 5 years shows AbCellera Biologics' Change in Receivables stood at $3.1 million in 2021, then soared by 522.83% to $19.0 million in 2022, then slumped by 45.18% to $10.4 million in 2023, then skyrocketed by 99.86% to $20.9 million in 2024, then crashed by 82.68% to $3.4 million in 2025.
  • Its Change in Receivables stands at $3.4 million for Q3 2025, versus $11.4 million for Q2 2025 and $1.1 million for Q1 2025.